Symbols / AGEN
AGEN Chart
About
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 116.38M |
| Enterprise Value | 145.46M | Income | -35.38M | Sales | 106.83M |
| Book/sh | -8.35 | Cash/sh | 0.10 | Dividend Yield | — |
| Payout | 0.00% | Employees | 316 | IPO | — |
| P/E | — | Forward P/E | 1.65 | PEG | — |
| P/S | 1.09 | P/B | -0.39 | P/C | — |
| EV/EBITDA | -2.89 | EV/Sales | 1.36 | Quick Ratio | 0.03 |
| Current Ratio | 0.47 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.57 | EPS next Y | 1.96 | EPS Growth | — |
| Revenue Growth | 20.40% | Earnings | 2026-03-10 | ROA | -16.66% |
| ROE | — | ROIC | — | Gross Margin | 0.08% |
| Oper. Margin | -16.08% | Profit Margin | -32.92% | Shs Outstand | 36.14M |
| Shs Float | 31.26M | Short Float | 10.81% | Short Ratio | 4.33 |
| Short Interest | — | 52W High | 7.34 | 52W Low | 1.38 |
| Beta | 1.61 | Avg Volume | 668.90K | Volume | 407.48K |
| Target Price | $12.33 | Recom | None | Prev Close | $3.07 |
| Price | $3.22 | Change | 4.89% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$12.33
Mean price target
2. Current target
$3.22
Latest analyst target
3. DCF / Fair value
$-73.85
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.22
Low
$6.00
High
$23.00
Mean
$12.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-10 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2025-08-28 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2025-06-04 | main | Baird | Neutral → Neutral | $6 |
| 2025-06-04 | up | HC Wainwright & Co. | Neutral → Buy | $25 |
| 2025-05-13 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-05-13 | main | Baird | Neutral → Neutral | $4 |
| 2025-04-30 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-03-18 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-03-12 | main | Baird | Neutral → Neutral | $3 |
| 2025-03-12 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-01-22 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-12-05 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-29 | reit | HC Wainwright & Co. | Neutral → Neutral | $7 |
| 2024-11-12 | main | HC Wainwright & Co. | Neutral → Neutral | $7 |
| 2024-08-14 | main | B. Riley Securities | Buy → Buy | $18 |
| 2024-07-19 | down | Jefferies | Buy → Hold | $7 |
| 2024-07-18 | down | HC Wainwright & Co. | Buy → Neutral | $9 |
| 2024-06-28 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2024-05-24 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2024-05-07 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
- Agenus (AGEN) Presents New Phase 1b Clinical Data on BOT/BAL Combination for MSS mCRC - Yahoo Finance UK ue, 24 Feb 2026 14
- How inflammation shapes 'cold' tumors: Agenus BOT/BAL data shown at AACR-IO - Stock Titan Mon, 09 Feb 2026 08
- AGENUS Earnings Results: $AGEN Reports Quarterly Earnings | AGEN Stock News - Quiver Quantitative Mon, 10 Nov 2025 08
- Can Agenus Stock Recover If Markets Fall? - Trefis Sun, 21 Dec 2025 08
- Agenus stock price target lowered to $23 by H.C. Wainwright on higher expenses - Investing.com ue, 12 Aug 2025 07
- Agenus: Cash Starved Pharma Counting On Bot/Bal Cancer Bounty (NASDAQ:AGEN) - Seeking Alpha ue, 12 Aug 2025 07
- Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance Mon, 14 Jul 2025 07
- Agenus (Nasdaq: AGEN) taps Dr José Iglesias to lead BOT/BAL medical affairs and France AAC - Stock Titan ue, 18 Nov 2025 08
- Agenus Inc. (AGEN) Surges After Zydus Agreement, Analysts Upbeat on Stock - Yahoo Finance Mon, 16 Jun 2025 07
- Agenus (NASDAQ: AGEN) 2025 Webcast to Highlight Phase 3 BATTMAN BOT/BAL CRC Study - Stock Titan Wed, 19 Nov 2025 08
- Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance ue, 13 Jan 2026 08
- How Agenus plans wider BOT+BAL access for cancer patients in Jan. 28 webcast - Stock Titan ue, 20 Jan 2026 08
- Despite Fast-paced Momentum, Agenus (AGEN) Is Still a Bargain Stock - Yahoo Finance Mon, 19 May 2025 07
- Cancer combo shows 42% 2yr survival as $141M immunotherapy deal closes - Stock Titan hu, 15 Jan 2026 08
- New Zylidac Bio sites help secure U.S. biologic drug supply chains - Stock Titan hu, 15 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 5027 | 14779 | — | Stock Award(Grant) at price 2.94 per share. | ARMEN GARO H. | Chief Executive Officer | — | 2026-02-06 00:00:00 | D |
| 1 | 4562 | 14781 | — | Stock Award(Grant) at price 3.24 per share. | ARMEN GARO H. | Chief Executive Officer | — | 2026-01-23 00:00:00 | D |
| 2 | 3780 | 14780 | — | Stock Award(Grant) at price 3.91 per share. | ARMEN GARO H. | Chief Executive Officer | — | 2026-01-09 00:00:00 | D |
| 3 | 7691 | 24842 | — | Stock Award(Grant) at price 3.23 per share. | HARRISON THOMAS L | Director | — | 2026-01-02 00:00:00 | D |
| 4 | 4942 | 16358 | — | Stock Award(Grant) at price 3.31 per share. | ARMEN GARO H. | Chief Executive Officer | — | 2025-12-26 00:00:00 | D |
| 5 | 4316 | 16358 | — | Stock Award(Grant) at price 3.79 per share. | ARMEN GARO H. | Chief Executive Officer | — | 2025-12-12 00:00:00 | D |
| 6 | 3587 | 16357 | — | Stock Award(Grant) at price 4.56 per share. | ARMEN GARO H. | Chief Executive Officer | — | 2025-11-28 00:00:00 | D |
| 7 | 3769 | 16357 | — | Stock Award(Grant) at price 4.34 per share. | ARMEN GARO H. | Chief Executive Officer | — | 2025-11-14 00:00:00 | D |
| 8 | 4120 | 16356 | — | Stock Award(Grant) at price 3.97 per share. | ARMEN GARO H. | Chief Executive Officer | — | 2025-10-31 00:00:00 | D |
| 9 | 4216 | 16358 | — | Stock Award(Grant) at price 3.88 per share. | ARMEN GARO H. | Chief Executive Officer | — | 2025-10-17 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -105.26M | -146.48M | -160.72M | 49.07M |
| TotalUnusualItems | 3.95M | 556.00K | -1.12M | -5.28M |
| TotalUnusualItemsExcludingGoodwill | 3.95M | 556.00K | -1.12M | -5.28M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -227.21M | -245.76M | -220.07M | -23.93M |
| ReconciledDepreciation | 13.34M | 13.59M | 6.95M | 6.79M |
| ReconciledCostOfRevenue | 156.01M | 237.68M | 197.26M | 182.08M |
| EBITDA | -101.30M | -145.92M | -161.85M | 43.78M |
| EBIT | -114.64M | -159.51M | -168.79M | 36.99M |
| NetInterestIncome | -117.63M | -97.92M | -61.86M | -65.72M |
| InterestExpense | 117.63M | 97.92M | 61.86M | 65.72M |
| NormalizedIncome | -231.17M | -246.32M | -218.95M | -18.64M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -227.21M | -245.76M | -220.07M | -23.93M |
| TotalExpenses | 227.89M | 316.42M | 278.27M | 258.44M |
| TotalOperatingIncomeAsReported | -120.47M | -159.55M | -179.43M | 25.75M |
| DilutedAverageShares | 21.47M | 17.89M | 14.09M | 11.45M |
| BasicAverageShares | 21.47M | 17.89M | 14.09M | 11.45M |
| DilutedEPS | -10.59 | -13.75 | -15.64 | -2.20 |
| BasicEPS | -10.59 | -13.75 | -15.64 | -2.20 |
| DilutedNIAvailtoComStockholders | -227.43M | -245.97M | -220.29M | -24.14M |
| NetIncomeCommonStockholders | -227.43M | -245.97M | -220.29M | -24.14M |
| PreferredStockDividends | 215.00K | 213.00K | 212.00K | 211.00K |
| NetIncome | -227.21M | -245.76M | -220.07M | -23.93M |
| MinorityInterests | 5.06M | 11.68M | 10.58M | 4.80M |
| NetIncomeIncludingNoncontrollingInterests | -232.27M | -257.44M | -230.66M | -28.72M |
| NetIncomeContinuousOperations | -232.27M | -257.44M | -230.66M | -28.72M |
| PretaxIncome | -232.27M | -257.44M | -230.66M | -28.72M |
| OtherIncomeExpense | 9.78M | 593.00K | 11.45M | -233.00K |
| OtherNonOperatingIncomeExpenses | 5.83M | 37.00K | 12.57M | 5.05M |
| SpecialIncomeCharges | 3.95M | 556.00K | -1.12M | -5.28M |
| OtherSpecialCharges | 1.94M | -6.20M | ||
| RestructuringAndMergernAcquisition | -3.95M | -556.00K | -815.00K | 11.48M |
| NetNonOperatingInterestIncomeExpense | -117.63M | -97.92M | -61.86M | -65.72M |
| InterestExpenseNonOperating | 117.63M | 97.92M | 61.86M | 65.72M |
| OperatingIncome | -124.43M | -160.10M | -180.24M | 37.23M |
| OperatingExpense | 71.88M | 78.74M | 81.01M | 76.36M |
| SellingGeneralAndAdministration | 71.88M | 78.74M | 81.01M | 76.36M |
| GeneralAndAdministrativeExpense | 71.88M | 78.74M | 81.01M | 76.36M |
| OtherGandA | 71.88M | 78.74M | 81.01M | 76.36M |
| GrossProfit | -52.55M | -81.37M | -99.23M | 113.59M |
| CostOfRevenue | 156.01M | 237.68M | 197.26M | 182.08M |
| TotalRevenue | 103.46M | 156.31M | 98.02M | 295.67M |
| OperatingRevenue | 2.48M | 41.74M | 52.74M | 251.13M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 23.63M | 19.72M | 15.28M | 12.84M |
| ShareIssued | 23.63M | 19.72M | 15.28M | 12.84M |
| TotalDebt | 94.87M | 88.47M | 78.43M | 58.29M |
| TangibleBookValue | -353.85M | -189.47M | -92.97M | 1.08M |
| InvestedCapital | -293.21M | -147.42M | -48.12M | 47.99M |
| WorkingCapital | -175.83M | -143.48M | 24.17M | 175.03M |
| NetTangibleAssets | -353.85M | -189.47M | -92.97M | 1.08M |
| CapitalLeaseObligations | 61.70M | 75.56M | 65.27M | 44.74M |
| CommonStockEquity | -326.38M | -160.33M | -61.28M | 34.44M |
| TotalCapitalization | -295.91M | -147.56M | -48.69M | 47.26M |
| TotalEquityGrossMinorityInterest | -306.42M | -148.38M | -54.90M | 47.91M |
| MinorityInterest | 19.96M | 11.95M | 6.38M | 13.47M |
| StockholdersEquity | -326.38M | -160.33M | -61.28M | 34.44M |
| GainsLossesNotAffectingRetainedEarnings | -1.40M | -955.00K | 915.00K | 1.49M |
| OtherEquityAdjustments | -1.40M | -955.00K | 915.00K | 1.49M |
| TreasuryStock | 0.00 | 0.00 | ||
| RetainedEarnings | -2.18B | -1.96B | -1.71B | -1.49B |
| AdditionalPaidInCapital | 1.86B | 1.80B | 1.64B | 1.52B |
| CapitalStock | 236.00K | 197.00K | 3.06M | 2.57M |
| CommonStock | 236.00K | 197.00K | 3.06M | 2.57M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 532.70M | 462.30M | 468.46M | 418.05M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 311.29M | 206.40M | 279.51M | 261.11M |
| OtherNonCurrentLiabilities | 225.13M | 129.98M | 202.45M | 194.97M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| NonCurrentDeferredLiabilities | 1.14M | 1.14M | 1.14M | 11.20M |
| NonCurrentDeferredRevenue | 1.14M | 1.14M | 1.14M | 11.20M |
| LongTermDebtAndCapitalLeaseObligation | 85.02M | 75.28M | 75.91M | 54.93M |
| LongTermCapitalLeaseObligation | 54.55M | 62.51M | 63.33M | 42.11M |
| LongTermDebt | 30.47M | 12.77M | 12.58M | 12.82M |
| CurrentLiabilities | 221.40M | 255.90M | 188.95M | 156.94M |
| OtherCurrentLiabilities | 121.85M | 141.21M | 101.49M | 75.66M |
| CurrentDeferredLiabilities | 31.00K | 18.00K | 12.27M | 12.43M |
| CurrentDeferredRevenue | 31.00K | 18.00K | 12.27M | 12.43M |
| CurrentDebtAndCapitalLeaseObligation | 9.85M | 13.19M | 2.52M | 3.35M |
| CurrentCapitalLeaseObligation | 7.15M | 13.04M | 1.94M | 2.63M |
| CurrentDebt | 2.70M | 146.00K | 575.00K | 728.00K |
| OtherCurrentBorrowings | 2.55M | 429.00K | 582.00K | |
| CurrentNotesPayable | 146.00K | 146.00K | 146.00K | 146.00K |
| PayablesAndAccruedExpenses | 89.67M | 101.48M | 72.68M | 65.50M |
| CurrentAccruedExpenses | 28.20M | 40.03M | 31.74M | 35.01M |
| Payables | 61.47M | 61.45M | 40.94M | 30.49M |
| AccountsPayable | 61.47M | 61.45M | 40.94M | 30.49M |
| TotalAssets | 226.27M | 313.91M | 413.56M | 465.96M |
| TotalNonCurrentAssets | 180.70M | 201.50M | 200.43M | 133.98M |
| OtherNonCurrentAssets | 5.83M | 9.34M | 4.45M | 9.54M |
| GoodwillAndOtherIntangibleAssets | 27.47M | 29.13M | 31.70M | 33.36M |
| OtherIntangibleAssets | 3.38M | 4.41M | 6.23M | 8.49M |
| Goodwill | 24.09M | 24.72M | 25.47M | 24.88M |
| NetPPE | 147.40M | 163.03M | 164.29M | 91.08M |
| AccumulatedDepreciation | -72.55M | -61.94M | -54.08M | -50.54M |
| GrossPPE | 219.95M | 224.97M | 218.36M | 141.62M |
| Leases | 94.86M | 95.64M | 28.76M | 28.66M |
| ConstructionInProgress | 784.00K | 1.51M | 66.46M | 16.84M |
| OtherProperties | 27.31M | 29.61M | 31.27M | 31.05M |
| MachineryFurnitureEquipment | 78.87M | 80.08M | 73.93M | 41.47M |
| BuildingsAndImprovements | 5.84M | 5.84M | 5.65M | 5.63M |
| LandAndImprovements | 12.29M | 12.29M | 12.29M | 17.97M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 45.57M | 112.42M | 213.12M | 331.97M |
| OtherCurrentAssets | 2.42M | 2.37M | 3.19M | 3.17M |
| PrepaidAssets | 2.31M | 8.10M | 13.83M | 20.36M |
| Receivables | 407.00K | 25.84M | 2.74M | 1.52M |
| AccountsReceivable | 407.00K | 25.84M | 2.74M | 1.52M |
| CashCashEquivalentsAndShortTermInvestments | 40.44M | 76.11M | 193.36M | 306.92M |
| OtherShortTermInvestments | 0.00 | 14.68M | 14.99M | |
| CashAndCashEquivalents | 40.44M | 76.11M | 178.67M | 291.93M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -158.89M | -234.16M | -228.44M | -23.67M |
| RepurchaseOfCapitalStock | 0.00 | -5.17M | -3.79M | -1.65M |
| RepaymentOfDebt | -10.48M | -8.93M | -490.00K | -1.32M |
| IssuanceOfDebt | 20.00M | 0.00 | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 38.82M | 133.16M | 99.21M | 220.65M |
| CapitalExpenditure | -576.00K | -9.95M | -53.06M | -33.81M |
| InterestPaidSupplementalData | 2.28M | 3.17M | 1.14M | 1.15M |
| EndCashPosition | 44.07M | 79.78M | 181.34M | 294.60M |
| BeginningCashPosition | 79.78M | 181.34M | 294.60M | 102.50M |
| EffectOfExchangeRateChanges | -260.00K | -628.00K | -104.00K | -164.00K |
| ChangesInCash | -35.45M | -100.94M | -113.15M | 192.26M |
| FinancingCashFlow | 122.84M | 119.87M | 95.83M | 225.26M |
| CashFlowFromContinuingFinancingActivities | 122.84M | 119.87M | 95.83M | 225.26M |
| NetOtherFinancingCharges | 73.85M | -606.00K | -1.54M | |
| ProceedsFromStockOptionExercised | 647.00K | 807.00K | 898.00K | 9.13M |
| NetCommonStockIssuance | 38.82M | 127.98M | 95.42M | 218.99M |
| CommonStockPayments | 0.00 | -5.17M | -3.79M | -1.65M |
| CommonStockIssuance | 38.82M | 133.16M | 99.21M | 220.65M |
| NetIssuancePaymentsOfDebt | 9.52M | -8.93M | -490.00K | -1.32M |
| NetLongTermDebtIssuance | 9.52M | -8.93M | -490.00K | -1.32M |
| LongTermDebtPayments | -10.48M | -8.93M | -490.00K | -1.32M |
| LongTermDebtIssuance | 20.00M | 0.00 | 0.00 | 0.00 |
| InvestingCashFlow | 27.00K | 3.40M | -33.61M | -43.15M |
| CashFlowFromContinuingInvestingActivities | 27.00K | 3.40M | -33.61M | -43.15M |
| NetInvestmentPurchaseAndSale | 579.00K | 9.99M | 371.00K | -14.99M |
| SaleOfInvestment | 579.00K | 30.03M | 25.00M | 0.00 |
| PurchaseOfInvestment | 0.00 | -20.04M | -24.63M | -14.99M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -2.92M | 0.00 |
| PurchaseOfBusiness | 0.00 | 0.00 | -2.92M | 0.00 |
| NetPPEPurchaseAndSale | -552.00K | -6.59M | -31.06M | -28.16M |
| SaleOfPPE | 24.00K | 3.36M | 22.00M | 5.66M |
| PurchaseOfPPE | -576.00K | -9.95M | -53.06M | -33.81M |
| OperatingCashFlow | -158.31M | -224.20M | -175.37M | 10.14M |
| CashFlowFromContinuingOperatingActivities | -158.31M | -224.20M | -175.37M | 10.14M |
| ChangeInWorkingCapital | 32.60M | 10.76M | 24.08M | -9.74M |
| ChangeInOtherWorkingCapital | -671.00K | -13.79M | 3.57M | -13.98M |
| ChangeInPayablesAndAccruedExpense | 2.15M | 41.98M | 8.53M | 9.76M |
| ChangeInAccruedExpense | 136.00K | 20.61M | 2.03M | -1.06M |
| ChangeInPayable | 2.01M | 21.37M | 6.49M | 10.82M |
| ChangeInAccountPayable | 2.01M | 21.37M | 6.49M | 10.82M |
| ChangeInPrepaidAssets | 5.78M | 6.03M | 11.87M | -5.13M |
| ChangeInInventory | 0.00 | |||
| ChangeInReceivables | 25.34M | -23.46M | 122.00K | -394.00K |
| ChangesInAccountReceivables | 25.34M | -23.46M | 122.00K | -394.00K |
| OtherNonCashItems | 13.23M | -12.01M | 19.61M | 31.75M |
| StockBasedCompensation | 17.39M | 22.87M | 18.34M | 19.58M |
| AssetImpairmentCharge | 1.97M | 0.00 | 6.11M | 0.00 |
| DepreciationAmortizationDepletion | 13.34M | 13.59M | 6.95M | 6.79M |
| DepreciationAndAmortization | 13.34M | 13.59M | 6.95M | 6.79M |
| OperatingGainsLosses | -4.59M | -1.96M | -19.80M | -9.50M |
| GainLossOnInvestmentSecurities | -3.95M | -556.00K | -815.00K | |
| NetIncomeFromContinuingOperations | -232.27M | -257.44M | -230.66M | -28.72M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AGEN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|